AMGN:NASDAQ
Amgen Inc
$402.98
arrow_downward
-0.01%(-0.060) 1D
$405.17
arrow_upward
+0.54% (+2.19)todayPre-market
Closed: Oct 5, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMGN...
Open
$399.03
High
$403.69
Low
$397.03
Mkt. cap
217.86B
Avg. vol.
2.93M
Volume
0.00
Dividend
2.50%
Quarterly dividend
$2.52
Ex-dividend date
Aug 21, 2026
P/E ratio
25.03
52-wk high
$447.01
52-wk low
$288.00
EPS
$16.10
Beta
0.41
Shares outstanding
540.63M
No. of employees
32K
Open
$399.03
High
$403.69
Low
$397.03
Mkt. cap
217.86B
Avg. vol.
2.93M
Volume
0.00
Dividend
2.50%
Quarterly dividend
$2.52
Ex-dividend date
Aug 21, 2026
P/E ratio
25.03
52-wk high
$447.01
52-wk low
$288.00
EPS
$16.10
Beta
0.41
Shares outstanding
540.63M
No. of employees
32K
News stories
From web sources and news partners
MarketBeat
·
50 minutes ago
Amgen Inc. $AMGN Shares Purchased by MassMutual Private Wealth & Trust FSB
AD HOC NEWS
·
1 hour ago
Amgen stock pre-market at EUR 360.03: plus 0.28 percent
매일경제
·
7 hours ago
Hello, I'm "MK Signal," an AI reporter who analyzes U.S. stock hot issues.A buy signal for AMGN has
GuruFocus
·
12 hours ago
Is AMGN Overvalued? DCF Says Worth $189
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31.5K
Founded1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com